Search results
Results From The WOW.Com Content Network
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [ 19 ] [ 20 ] [ 21 ] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain .
Side effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, [citation needed] it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate management.
Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin. [6] (subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.
Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes. [3][4] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth. [1][2] The most common side effects include genital yeast infections, urinary tract infections, and increased ...
Semaglutide is not a WHO-recommended treatment for diabetes management due to its current high cost, but the agency said it was working on a rapid advice guideline on use of GLP-1 drugs for ...
SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. [2] [3] As of 2014, several medications of this class had been approved or were under development. [4]
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
After 670 days, there were 1,172 new diagnoses of dementia among the study participants. When compared with people who took DPP-4 inhibitors, those who took SGLT-2 inhibitors had a 35 percent ...